ReviewInternational journal of molecular sciences2026
Deubiquitinases as Regulators and Therapeutic Targets in Vascular Diseases.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Ubiquitination and deubiquitination are dynamic post-translational regulatory processes that control protein stability and signaling. Deubiquitinases (DUBs), which remove ubiquitin chains from target proteins, have emerged as important regulators of vascular homeostasis and disease. In this review, we summarize recent progress in defining the roles of DUBs in major vascular pathologies, including vascular inflammation, remodeling, neointimal formation, angiogenesis, endothelial barrier dysfunction, thrombosis, and fibrosis. Accumulating evidence indicates that distinct DUBs act in a cell type- and context-dependent manner in endothelial cells, vascular smooth muscle cells, immune cells, and fibroblasts, contributing to vascular diseases such as aortic aneurysm, atherosclerosis, pulmonary hypertension, ischemic stroke, and intimal hyperplasia. These findings support DUBs as key regulatory nodes integrating ubiquitin signaling with inflammatory and stress-response pathways in the vasculature. In parallel, efforts to pharmacologically modulate DUB activity have led to the development of selective inhibitors and activators, although challenges remain in achieving substrate specificity and tissue selectivity. Overall, DUBs represent promising therapeutic targets for vascular disease, and future studies should focus on defining disease-specific DUB-substrate networks and developing context-dependent strategies for precise vascular intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.